Previous studies have confirmed that IL-1 is a key mediator of the inflammatory response in acute coronary syndrome (ACS), and IL-1 blockade with anakinra significantly inhibited CRP levels (at least partially) (Abbate et al., 2010; Abbate et al., 2013; Morton et al., 2015). The gene discussed is CRP; the disease is acute coronary syndrome.